This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsuki, H. Articles by Seiki, M. Search for Related Content PubMed PubMed Citation Articles by Matsuki, H. Articles by Seiki, M.

Monoclonal Antibodies with Defined Recognition Sequences in the Stem Region of CD44

Detection of Differential Glycosylation of CD44 between Tumor and Stromal Cells in Tissue

¹ Division of Cancer Cell Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan;
² Pharmaceutical Development Section, Research Institute, Daiichi Fine Chemical, Ltd., Takaoka, Japan; and
³ Department of Pathology, School of Medicine, Keio University, Tokyo, Japan

CD44 is an enigmatic cell adhesion molecule acting as a major receptor for hyaluronan and playing roles in many biological and pathological processes such as lymphocyte homing, T-cell activation, wound healing, angiogenesis, and metastatic spread of tumor cells. However, the complexity of the molecule, with its alternatively spliced variants, extensive glycosylation, and processing by different proteases, has hampered detailed analysis. In this study, we prepared four monoclonal antibodies (285-2F12, 284-43F1, 268-1F5, and 294-6F2) and one polyclonal antibody (C6) that recognize defined sequences in the stem region of CD44H. Interestingly, two of the monoclonal antibodies, 268-1F5 and 294-6F2, failed to recognize the CD44 expressed in five of the seven human tumor cell lines examined by Western blotting. Treatment of the samples with a combination of neuraminidase and O-glycosidase as well as the expression of mutants with site-directed mutations at possible modification sites rendered the CD44 reactive to the antibodies. Thus, the reactivity of the antibodies is sensitive to O-glycosylation presumably near the recognition sites. Glycosylation of CD44 that affects reactivity to the antibodies was found to be regulated differentially between tumor and stromal cells in two breast and three oral carcinoma tissues. Antibody 268-1F5 reacted to the tumor cells, but not to the cells in the surrounding stroma. On the other hand, the reactivity of 294-6F2 to the cells was opposite between the two tumor types. Thus, these sets of antibodies are useful to detect and analyze the as-yet-unknown roles of site-specific glycosylation of CD44, particularly in tumors.

This article has been cited by other articles:

				L. K. Diaz, X. Zhou, E. T. Wright, M. Cristofanilli, T. Smith, Y. Yang, N. Sneige, A. Sahin, and M. Z. Gilcrease CD44 Expression Is Associated with Increased Survival in Node-Negative Invasive Breast Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3309 - 3314. [Abstract] [Full Text] [PDF]

				H. Nakamura, N. Suenaga, K. Taniwaki, H. Matsuki, K. Yonezawa, M. Fujii, Y. Okada, and M. Seiki Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase Cancer Res., February 1, 2004; 64(3): 876 - 882. [Abstract] [Full Text] [PDF]